• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
    • Just look at what our Tens of Thousands of Satisfied Customers say about us
    Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Aurobindo > February 03, 2011

      Aurobindo Pharma receives USFDA approval

      Posted Atindiainfoline.com

      Aurobindo Pharma has received tentative approval from the USFDA to manufacture and market Famciclovir tablets in the strengths of 125mg, 250mg and 500mg.

      Famciclovir tables is the generic version of Novartis Pharmaceuticals Corp's Famvir tablets and is indicated for the treatment of recurrent mucocutaneous herpes simplex infections in HIV-infected patients and suppression of recurrent genital herpes in immunocompetent patients. The product has a market size of approximately US$ 170 million for the twelve months ended September 2010 according to IMS.

      The company made this announcement during the trading hours on, 31 January 2011.

      Feb 03, 2011


       

      Share this Article!

    Back to top^